鞘内药物输注系统治疗慢性难治性非癌痛的系统综述与荟萃分析
该系统综述与荟萃分析纳入39项研究共2652例慢性非癌痛患者,评估鞘内药物输注(ITDD)的临床结局与不良事件。随机效应荟萃分析显示12个月时疼痛较基线平均降低2.64分(95%CI 2.19-3.08),95%预测区间0.734-4.54分。所有研究报告功能与健康相关生活质量较基线改善,但不良事件报告不一致,证据确定性低。
要点
- ITDD与慢性非癌痛患者疼痛较基线有临床意义降低相关。
- 12个月疼痛平均降低2.64分,新研究变化超过2分最小临床重要差异的概率为75%。
- 功能和健康相关生活质量均较基线改善,但证据确定性低至极低。
核心结论
- ITDD与慢性非癌痛患者疼痛较基线有意义的降低相关,并改善功能与健康相关生活质量。
- 因研究局限性,疼痛结局证据确定性低,其他结局证据确定性极低。
- 需要改进报告和开展对照试验以加强证据基础,并审慎考虑维持临床均势的对照干预。
研究设计与样本
- 遵循PRISMA指南并注册方案(CRD42024581505)的系统综述与荟萃分析。
- 检索MEDLINE、EMBASE、CENTRAL和WikiStim截至2024年9月,纳入报告疼痛强度、功能、健康相关生活质量及不良事件的ITDD非癌痛受者研究。
- 共纳入39项研究(n=2652),其中20项单臂比较进入荟萃分析。
- 采用随机效应荟萃分析评估12个月时间点疼痛强度结局(0-10分等效量表)。
- 使用美国国立卫生研究院和Cochrane工具评估偏倚风险。
主要发现
- 疼痛较基线汇总平均降低2.64分(95%CI 2.19至3.08)。
- 考虑研究间效应量异质性,95%预测区间为0.734至4.54分。
- 新开展的类似研究中,疼痛较基线变化超过最小临床重要差异2分的概率为75%(95%CI 68%至83%)。
- 所有研究报告功能和健康相关生活质量较基线改善。
- 不良事件报告或因不良事件终止ITDD的报告不一致。
关键数值与推荐
- 疼痛强度结局采用0-10分等效量表评估,最小临床重要差异为2分。
- 队列研究和前后对照研究偏倚风险为中等或高。
- 两项交叉随机试验和一项平行组随机试验偏倚风险为低,一项平行组随机试验偏倚风险为高。
临床怎么用
- ITDD可考虑用于慢性难治性非癌痛患者,预期疼痛较基线有临床意义降低。
- 应关注功能和健康相关生活质量的潜在改善。
- 临床决策需考虑证据确定性低,并注意不良事件报告不一致。
局限性
- 疼痛结局证据确定性低,其他结局证据确定性极低。
- 不良事件或因不良事件终止ITDD的报告不一致。
- 队列研究和前后对照研究偏倚风险为中等或高,一项平行组随机试验偏倚风险为高。
- 需要改进报告和开展对照试验以加强证据基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/IMPORTANCE: Intrathecal drug delivery (ITDD) is an established intervention for chronic non-cancer pain, cancer pain, and spasticity. However, ITDD is not routinely commissioned for non-cancer pain in some countries, including England. A comprehensive synthesis of its clinical impact and safety profile in this population is lacking. OBJECTIVE: To investigate the clinical outcomes and adverse events (AEs) associated with ITDD in adults with chronic non-cancer pain. EVIDENCE REVIEW: A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and a registered protocol (CRD42024581505). Searches across MEDLINE, EMBASE, CENTRAL, and WikiStim until September 2024 were performed to identify studies reporting pain intensity, function, health-related quality of life (HRQoL), and AEs in ITDD recipients with non-cancer pain. Risk of bias was assessed using National Institutes of Health and Cochrane tools. A random-effects meta-analysis was performed on the pain intensity outcome (0-10 scale equivalent) at the 12-month time point. FINDINGS: 39 studies (n=2652) were included; 20 single-arm comparisons contributed to meta-analysis. The pooled mean reduction in pain from baseline was 2.64 (95% CI 2.19 to 3.08). Accounting for between-study heterogeneity in effect size, the 95% prediction interval is 0.734 to 4.54 units. The probability that the change from baseline in a new, similar study would be greater than the minimum clinically important difference of 2 units is 75% (95% CI 68% to 83%). All studies reported improvements from baseline in function and HRQoL. Reporting of AEs or discontinuation of ITDD due to AEs was inconsistent. Risk of bias was moderate or high for cohort studies and pre-post studies, low for two crossover randomized trials and one parallel-arm randomized trial, and high for one parallel-arm randomized trial. CONCLUSIONS: ITDD is associated with meaningful reductions in pain from baseline, and functional and HRQoL improvement in patients with chronic non-cancer pain. However, the certainty of evidence is low for pain and very low for other outcomes due to study limitations. Improved reporting and controlled trials are needed to strengthen the evidence base, with careful consideration of a control intervention that maintains clinical equipoise.
引用
- Duarte RV, Copley S, Batterham A, et al. Systematic review and meta-analysis of intrathecal drug delivery systems for the treatment of chronic refractory non-cancer pain. Reg Anesth Pain Med. 2026. PMID: 42710940. doi:10.1136/rapm-2025-107226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。